Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingfeng Zhu

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Nature Communications|February 24, 2026
iCLAP: an innovative method for integrable co-detection of low-abundance antigens with high-plex immunostainingFan Wu, Shuyuan Zheng, Yani Chen, et al.
Nature Communications|June 20, 2023
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinomaThatcher Heumann, Carol Judkins, Keyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancerThatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Nature Cancer|February 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trialEvanthia T Roussos Torres, Won J Ho, Ludmila Danilova, et al.
Nature Cancer|November 19, 2021
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor ImmunityWon Jin Ho, Qingfeng Zhu, Jennifer Durham, et al.
Cancer Immunology Research|August 15, 2025
Neoadjuvant immunotherapy promotes the formation of mature tertiary lymphoid structures in a remodeled pancreatic tumor microenvironmentDimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic respondersDimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, et al.
Cell Systems|April 20, 2023
Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spacesAtul Deshpande, Melanie Loth, Dimitrios N Sidiropoulos, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Nature Communications|February 24, 2026
iCLAP: an innovative method for integrable co-detection of low-abundance antigens with high-plex immunostainingFan Wu, Shuyuan Zheng, Yani Chen, et al.
Nature Communications|June 20, 2023
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinomaThatcher Heumann, Carol Judkins, Keyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancerThatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Nature Cancer|February 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trialEvanthia T Roussos Torres, Won J Ho, Ludmila Danilova, et al.
Nature Cancer|November 19, 2021
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor ImmunityWon Jin Ho, Qingfeng Zhu, Jennifer Durham, et al.
Cancer Immunology Research|August 15, 2025
Neoadjuvant immunotherapy promotes the formation of mature tertiary lymphoid structures in a remodeled pancreatic tumor microenvironmentDimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic respondersDimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, et al.
Cell Systems|April 20, 2023
Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spacesAtul Deshpande, Melanie Loth, Dimitrios N Sidiropoulos, et al.
Pageof 12